Celldex Therapeutics to present poster on its first antibody-drug conjugate product

Download PDF Copy

Dec 8 2009

NewsGuard 100/100 Score

Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the Company’s first antibody-drug conjugate (ADC) product candidate, CDX-011 (formerly CR011-vcMMAE), for the treatment of locally advanced or metastatic breast cancer will be the subject of a poster presentation at the 2009 San Antonio Breast Cancer Symposium.

Poster #6096, “A Phase I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer,” will include safety, tolerability and efficacy data. It is scheduled for presentation during Poster Session 6 in Exhibit Halls A-B from 7:00 a.m. to 9:00 a.m. CST on Sunday, December 13, 2009 at the Henry B. Gonzalez Convention Center in San Antonio, TX.

http://www.celldextherapeutics.com

Posted in: Women's Health News | Pharmaceutical News

Tags: Antibody, Antibody-Drug Conjugate, Breast Cancer, Cancer, Efficacy, Immunotherapy, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Researchers develop new antibody with potential to treat several types of cancer

Researchers develop new antibody with potential to treat several types of cancer

Novel antibody shows promise for pain relief in peripheral nerves

Novel antibody shows promise for pain relief in peripheral nerves

New antibody platform targets evolving viruses

New antibody platform targets evolving viruses

Kyushu University team develops antibody to fight age-related muscle atrophy

Kyushu University team develops antibody to fight age-related muscle atrophy

Long-lived plasma cells fail to establish after COVID mRNA vaccination, limiting long-term antibody response

Long-lived plasma cells fail to establish after COVID mRNA vaccination, limiting long-term antibody response

New trial shows felzartamab reduces proteinuria in IgA nephropathy patients

New trial shows felzartamab reduces proteinuria in IgA nephropathy patients

Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform

Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform

Researchers uncover key to combat Campylobacter infections

Researchers uncover key to combat Campylobacter infections

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Elevated antibody responses to Epstein-Barr virus linked to increased risk of multiple sclerosis